Pulse.

a daily field guide to health research that matters

◆ Console

‹ back to Sun · 15 Nov 2026

Daily digest

Sun · 15 Nov 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

PubMed Daily Triage — 2026-11-15

Run ID: 2026-11-15-attempt1-20261115T100000Z | Attempt: 1 of 3
CRDT Window: 2026-11-14T00:00:00Z → 2026-11-15T23:59:59Z
Generated: 2026-11-15T10:00:00Z


Summary

Metric Value
Articles reviewed (unique PMIDs) 33
🔴 HIGH priority 4
🟡 STANDARD priority 29
🟢 LOW priority 0
Unsolicited sentinel finds 1
Topics with HIGH articles 3 (T1, T3, T7)

State note: state.json last_successful_run was 2026-06-27 (141 days stale); CRDT window derived from last canonical file date (2026-11-14).


🔴 HIGH Priority Articles

1 · PMID 43033821 — Score 9/10 · 🏷️ NOVEL_TREATMENT

CagriSema at lower dose levels achieves ~20% weight loss in Phase 3b RCT

Wharton S, Broholm C, Horn D, et al.
Lancet Diabetes Endocrinol · 2026 Nov 14 · Phase 3b multicentre double-blind RCT
Topic: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk

Key finding: CagriSema at 1·7 mg and 1·0 mg doses achieved −20·7% and −21·0% bodyweight reduction vs −2·0% with placebo at 68 weeks (p<0·0001), with 95–96% of participants meeting the ≥5% weight loss threshold. Both lower dose levels were significantly superior to placebo.

Why it matters: Extends the cagrilintide-semaglutide dosing landscape beyond the reference 2·4 mg dose, potentially broadening access and tolerability for obesity pharmacotherapy. Phase 3b design (n=309, 24 sites, 5 countries). Novo Nordisk funded.

Score breakdown: Novelty 2 · Relevance 3 · Design Quality 2 · Population/Unmet Need 2
Evidence maturity: Potentially Practice-Changing | Access: Abstract only


2 · PMID 43032647 — Score 8/10 · 🏷️ NOVEL_TREATMENT

HHT-based induction in CEBPA double-mutated AML: Phase II objectives met

Hui Y, Li F, Gong B, et al.
Cancer Pathog Ther · 2026 Nov (eCollection) · Prospective multicenter single-arm Phase II
Topic: Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)

Key finding: HAD induction (homoharringtonine + daunorubicin + cytarabine) in 61 newly diagnosed CEBPAdm AML patients achieved 93.4% CR after one cycle with MRD negativity in 79.3% of responders. 3-year EFS, RFS, and OS were 77.9%, 82.2%, and 87.3% — meeting all prespecified trial objectives.

Why it matters: First prospective multicenter Phase II trial confirming HHT-based induction specifically in CEBPAdm AML (~6–10% of AML). MRD negativity after a single induction cycle with strong 3-year survival rates supports HAD as a preferred induction regimen in this favorable-risk subset. PMC open access.

Score breakdown: Novelty 2 · Relevance 2 · Design Quality 2 · Population/Unmet Need 2
Evidence maturity: Validated | Access: PMC full text


3 · PMID 43032186 — Score 6/10 · 🏷️ EARLY_CANCER_DETECTION

XAI identifies circulating miRNA candidates for pancreatic cancer liquid biopsy

Mandal S, Ansari MA, Chanu WP.
Front Artif Intell · 2026 Oct 21 · Retrospective computational biomarker discovery
Topic: Early cancer detection (liquid biopsy, ctDNA, cfDNA)

Key finding: Bayesian stacked ensemble + SHAP-XAI applied to 5 GEO serum miRNA datasets (n=1,101 samples) achieved AUC=0.97 for pancreatic cancer detection, identifying 20 key miRNAs (hsa-miR-125a-3p, hsa-miR-1290, hsa-miR-614, hsa-miR-497-5p) with MAPK/CDK/TP53 pathway confirmation via DIANA-miRPath.

Why it matters: Pancreatic cancer early detection is a major unmet need (5-year OS ~12%); SHAP-based explainability addresses clinical interpretability requirements. Findings require independent prospective validation; ICMR affiliation. PMC open access.

Score breakdown: Novelty 2 · Relevance 2 · Design Quality 1 · Population/Unmet Need 1
Evidence maturity: Exploratory | Access: PMC full text


4 · PMID 43028462 — Score 6/10 · 🏷️ EARLY_CANCER_DETECTION

Circulating ncRNAs as early TNBC liquid biopsy biomarkers: state of the field

Kuleva I, Stoyanov S, Tsvetkova M, et al.
Diagnostics (Basel) · 2026 Oct 30 · Narrative review
Topic: Early cancer detection (liquid biopsy, ctDNA, cfDNA)

Key finding: Critical appraisal (2009–Oct 2026) of circulating miRNA, lncRNA, and circRNA biomarkers for early TNBC detection (stages I–II): miRNAs provide most direct evidence but remain insufficiently validated; lncRNAs/circRNAs predominantly exploratory. Translation requires standardised workflows, independent multicenter validation, and prospective intended-use evaluation.

Why it matters: TNBC lacks approved targeted therapies; early detection could enable curative-intent treatment. Review provides a rigorous clinical translation framework distinguishing discovery claims from clinical readiness. PMC open access.

Score breakdown: Novelty 2 · Relevance 2 · Design Quality 1 · Population/Unmet Need 1
Evidence maturity: Exploratory | Access: PMC full text


🟡 STANDARD Priority Articles

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

(1 HIGH above; 4 STANDARD below)

PMID Score Title (abbreviated) Study Design Flag
43033914 7 Real-world CAR-T access and barriers in R/R DLBCL: population-based study (Alberta, Canada) Retrospective population-based cohort UNDERSERVED_POPULATION
43033511 6 Therapy-related CML outcomes in TKI era: final CML Cooperative Study Group report (n=819, 33 TR-CML) Multicenter retrospective registry NONE
43032913 5 Decitabine-cedazuridine (ASTX727) in AML: pharmacology, efficacy, safety evaluation (MD Anderson review) Narrative review NEAR_TERM_IMPLEMENTABLE
43033585 5 BEGEV ± rituximab chemomobilization in R/R HL/NHL: multicenter Turkish experience (n=31, 100% mobilization success) Multicenter retrospective cohort NONE

Highlights: 43033914 (Transplant Cell Ther) provides population-level CAR-T utilization data in a universal healthcare system — 72% access rate, with poor fitness/uncontrolled disease (not geography) as dominant barriers. 43032913 from Garcia-Manero/Ravandi's MD Anderson group clarifies that oral HMA convenience is the main advantage over IV decitabine, not superior efficacy.


CBC-Based Diagnostics and Machine Learning in Hematology

PMID Score Title (abbreviated) Study Design Flag
43028369 5 CBC-derived hemorheological surrogates + angiography video features for FFR prediction (AUC 0.621, n=179) Retrospective pilot validation PROMISING_PRELIMINARY

Note: Only one on-topic article in this CRDT window. AUC 0.621 is below clinical utility threshold; establishes feasibility concept for CBC-hemorheology in cardiovascular AI.


Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

(2 HIGH above; 1 STANDARD below)

PMID Score Title (abbreviated) Study Design Flag
43026792 6 ctDNA across the PDAC patient journey: from molecular profiling to dynamic monitoring (Miyagi Cancer Center review) Narrative review PROMISING_PRELIMINARY

Highlight: 43026792 (Cancers, PMC) provides a clinically structured framework distinguishing established ctDNA utility (post-surgery MRD detection) from investigational monitoring applications in PDAC. Two search candidates were topic false positives for prenatal cfDNA (not cancer detection).


AI/ML in Clinical Diagnostics and Imaging

PMID Score Title (abbreviated) Study Design Flag
43033194 6 LLM (ChatGPT/Perplexity) vs pediatricians/radiologists for pediatric CXR interpretation (n=502 radiographs) Cross-sectional observational PROMISING_PRELIMINARY
43031732 6 Multimodal CT radiomics + 2.5D DL for preoperative grading of clear cell RCC: multicenter study (4 hospitals) Multicenter retrospective validation PROMISING_PRELIMINARY
43033331 6 CT-derived cardiometabolic biomarkers via fully automated DL in breast cancer (Johns Hopkins, n=127) Retrospective cross-sectional PROMISING_PRELIMINARY
43033525 5 HbA1c-anchored EBM for undiagnosed diabetes screening with offline on-device deployment (NHANES + BRFSS) Retrospective cross-sectional validation NEAR_TERM_IMPLEMENTABLE
43031778 5 ML + metabolomics for HFNC failure prediction in COVID-19 AHRF: AUC 0.91 in temporal validation (n=111) Prospective observational (temporal split) PROMISING_PRELIMINARY

Highlights: 43033194 (Pediatr Pulmonol) is the first rigorous head-to-head comparison of general-purpose LLMs vs specialists for pediatric CXR — ChatGPT approaches generalist paediatrician accuracy but falls well short of radiologists. 43033525 (Int J Med Inform) addresses self-report label bias in diabetes screening ML and deploys offline — practically novel for LMIC settings.


Precision Oncology and Genomic Medicine

(43033043 and 43032513 lead at score 7)

PMID Score Title (abbreviated) Study Design Flag
43033043 7 Cross-ancestry proteome-wide MR of 1,962 plasma proteins and breast cancer (JNCI; NCI/Harvard; n=361K+) Cross-ancestry proteome-wide MR PROMISING_PRELIMINARY
43032513 7 Access to precision oncology-based care in North America: tri-national synthesis (Lancet Americas; MSK/PMH) Narrative synthesis UNDERSERVED_POPULATION
43032917 5 Biomarkers in adaptive resistance in mCRC: ctDNA utility across EGFR/VEGF/BRAF/KRAS/HER2/ICI classes (Mayo) Narrative review NONE
43032993 5 Deep multi-omics fusion (cGAN + GAT) for cancer subtype classification: C-index 0.89 (Christ Univ/Northumbria) Retrospective computational PROMISING_PRELIMINARY

Highlights: 43033043 identifies LRRC25, PARK7, and LRRC37A2 as novel breast cancer susceptibility protein candidates with cross-ancestry MR + colocalization + All of Us replication. 43032513 proposes a tri-national precision oncology implementation agenda, flagging AI-trained genomic models as an equity risk if implementation reform lags.


Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

(43033914 score-7 shared with Hematologic Malignancies)

PMID Score Title (abbreviated) Study Design Flag
43033551 6 T-cell GP73 dynamics across 8 ICI cycles associate with clinical benefit in NSCLC (n=76; Lung Cancer) Prospective longitudinal observational PROMISING_PRELIMINARY
43033601 6 Pre-apheresis T-cell fitness as determinant of CAR-T manufacturing quality and efficacy (Tongji review) Narrative review PROMISING_PRELIMINARY
43032263 6 TKI + ICI to reprogram MSS CRC TME: STELLAR-303 Phase III interim shows OS benefit (ESMO GI Oncol) Narrative review referencing Phase III interim NEAR_TERM_IMPLEMENTABLE
43034147 5 Second-line ES-SCLC outcomes in immunotherapy era: AT regimens associated with worse OS (n=94; Cancer Med) Multicenter retrospective cohort NONE

Highlights: 43032263 (ESMO Gastrointest Oncol, PMC) is clinically important — it contextualizes the STELLAR-303 Phase III interim showing OS benefit for zanzalintinib + atezolizumab versus regorafenib in pretreated MSS CRC, a cancer subtype previously refractory to immunotherapy. If confirmed, this is a practice-changing result.


Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

(43033821 score-9 HIGH above; 5 STANDARD below)

PMID Score Title (abbreviated) Study Design Flag
43033966 7 VITAL RCT comprehensive results: omega-3 FA reduces MI (HR 0.72), autoimmune disease (HR 0.82) (n=25,871) Comprehensive RCT report NEAR_TERM_IMPLEMENTABLE
43033336 7 GLP-1 RA vs placebo in HFpEF: SR/MA of 3 RCTs (1,463 pts); HF events OR 0.32, no mortality benefit Systematic review and meta-analysis NEAR_TERM_IMPLEMENTABLE
43034104 6 GLP-1 RA in overweight/obesity + alcohol use disorder: retrospective cohort (Penn State; NIH NIDA/NIAAA) Retrospective cohort PROMISING_PRELIMINARY
43033835 6 NSTEMI socioeconomic inequalities persist under universal healthcare: Belgian nationwide study (n=64,890) Nationwide retrospective registry UNDERSERVED_POPULATION
43034020 5 KDM biological age acceleration × insulin resistance indices predict cardiometabolic multimorbidity (CHARLS) Prospective cohort PROMISING_PRELIMINARY

Highlights: 43033966 (VITAL, Manson JE et al, J Nutr) finalises the most comprehensive omega-3 FA RCT: targeted coronary and autoimmune benefits support selective rather than universal supplementation. 43034104 (Eur J Intern Med) documents emerging real-world evidence for GLP-1 RA in alcohol use disorder — a novel dual-benefit hypothesis with NIH author support; prospective RCT is needed.


Aging, Longevity, and Population Health

PMID Score Title (abbreviated) Study Design Flag
43030321 5 Blueberry dietary intervention feasibility in older adults with mild depression: pilot RCT (Beth Israel/Harvard) Pilot RCT PROMISING_PRELIMINARY
43031330 5 Exercise reprograms epigenetic-mitochondrial axis for healthy aging across muscle, brain, heart (Dev Neurobiol) Comprehensive narrative review PROMISING_PRELIMINARY
43030236 5 cMIND diet adherence associated with stable cognitive trajectories in Chinese elderly (CLHLS, n=1,755) Prospective longitudinal cohort PROMISING_PRELIMINARY

Note: T8 results this window are predominantly nutritional/lifestyle observational studies. The blueberry RCT (43030321) did not meet its 76% vs 80% feasibility threshold but high adherence supports further investigation.


Rare Diseases with High Unmet Need

PMID Score Title (abbreviated) Study Design Flag
43032770 5 Merkel cell carcinoma 15-year outcomes at UK tertiary centre: improved survival with immunotherapy adoption (n=81) Retrospective institutional cohort NONE

Note: Only 5 genuine rare-disease candidates in this CRDT window. 43032770 is the strongest match (MCC incidence ~0.3/100,000; aggressive prognosis). Three of five T9 candidates were false positives (shoulder arthroplasty, common malignancy, non-rare pain syndrome).


Sentinel (Unsolicited Find)

PMID Score Title (abbreviated) Study Design Flag
43033990 4 Next Steps clinician-peer aftercare for suicide prevention: null result NRT (n=81 participants; Wollongong) Non-randomized controlled trial NONE

Note: Null result — program did not demonstrate superiority over treatment-as-usual on primary outcomes. Peer worker integration is feasible; further RCT evaluation warranted.


Pipeline Flags Summary

Flag PMIDs
🔴 NOVEL_TREATMENT 43033821 · 43032647
🔴 EARLY_CANCER_DETECTION 43032186 · 43028462
🟡 NEAR_TERM_IMPLEMENTABLE 43033966 · 43033336 · 43032913 · 43033525 · 43032263
🟠 UNDERSERVED_POPULATION 43033914 · 43032513 · 43033835
🔵 PROMISING_PRELIMINARY 43033043 · 43034104 · 43033551 · 43033601 · 43031732 · 43033331 · 43033194 · 43026792 · 43032186 · 43031778 · 43028369 · 43032993 · 43030321 · 43031330 · 43030236 · 43032770 · 43034020 · 43034147
— NONE 43033511 · 43033585 · 43032917 · 43033990

Coverage & Quality Notes


Output A JSON: run-logs/2026-11-15-attempt1-20261115T100000Z-triage.tmp.json (101 KB, 33 articles)
Output B Digest: run-logs/2026-11-15-attempt1-20261115T100000Z-digest.tmp.md (this file)
Validator will promote to final paths upon validation pass.